December, 2016: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2016

New Patents Issued Across Multiple Geographies in US, Japan and Canada

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that
during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes more than 20 issued patents and many pending applications.